Erasca (ERAS) Equity Average (2020 - 2026)
Erasca posted quarterly Equity Average of $359.3 million for Q1 2026, down 12.67% year-on-year from $411.5 million in Q1 2025, and up 6.78% on a QoQ basis from $336.5 million in Q4 2025.
Erasca (ERAS) has 7 years of Equity Average data on file, last reported at $359.3 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average fell 12.67% year-over-year to $359.3 million; the trailing twelve-month figure through Mar 2026 stood at $359.3 million (down 12.67% YoY), and the FY2025 full-year result was $374.3 million, up 1.15% from the prior year.
- Equity Average for Q1 2026 stood at $359.3 million, up from $336.5 million in the prior quarter.
- Across five years, Equity Average topped out at $450.6 million in Q3 2024 and bottomed at $302.5 million in Q1 2024.
- The 5-year median for Equity Average is $380.2 million (2022), against an average of $381.4 million.
- The widest annual swing landed in 2022, when Equity Average jumped 462.27%; it then dropped 24.2% in 2024.
- A 5-year view of Equity Average shows it stood at $388.6 million in 2022, then decreased by 15.64% to $327.8 million in 2023, then surged by 33.23% to $436.8 million in 2024, then decreased by 22.95% to $336.5 million in 2025, then gained by 6.78% to $359.3 million in 2026.
- The last three Equity Average figures came in at $359.3 million (Q1 2026), $336.5 million (Q4 2025), and $360.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 359.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 359.35 Mn |
| Dec 31, 2025 | 336.53 Mn |
| Sep 30, 2025 | 360.07 Mn |
| Jun 30, 2025 | 385.88 Mn |
| Mar 31, 2025 | 411.50 Mn |
| Dec 31, 2024 | 436.77 Mn |
| Sep 30, 2024 | 450.56 Mn |
| Jun 30, 2024 | 369.75 Mn |
| Mar 31, 2024 | 302.55 Mn |
| Dec 31, 2023 | 327.83 Mn |
| Sep 30, 2023 | 350.84 Mn |
| Jun 30, 2023 | 374.58 Mn |
| Mar 31, 2023 | 399.15 Mn |
| Dec 31, 2022 | 388.59 Mn |
| Sep 30, 2022 | 380.19 Mn |
| Jun 30, 2022 | 409.86 Mn |
| Mar 31, 2022 | 440.60 Mn |
| Dec 31, 2021 | 469.76 Mn |
| Sep 30, 2021 | 166.50 Mn |
| Jun 30, 2021 | -139.63 Mn |
| Mar 31, 2021 | -121.62 Mn |
| Dec 31, 2020 | -83.40 Mn |
| Sep 30, 2020 | -47.69 Mn |